Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Smisson-Cartledge Biomedical
AddedFeb 16, 2024
UpdatedJun 18, 2026
Smisson-Cartledge Biomedical

Smisson-Cartledge Biomedical

Seed

Smisson-Cartledge Biomedical: Innovating therapeutic solutions with portable infusion systems since 1996.

HQ
Macon, GA, US
Founded
1996
Overview
Compare
Fundraising
Employees
Website

Founded in 1996, Smisson-Cartledge Biomedical is a medical device company dedicated to developing therapeutic solutions for thermal infusion care. Their core mission is to enhance patient outcomes through innovative medical technologies. The company's flagship product, the ThermaCor 1200 infusion system, is a portable device designed for various medical procedures, including hypothermia treatment, resuscitation, cardiac and transplant surgeries, and cancer treatment. Smisson-Cartledge Biomedical primarily focuses on the healthcare market, providing critical care solutions to hospitals and medical professionals.

Notable affiliated individuals include the founders, Dr. Fred Smisson and Dr. Robert Cartledge, who are key figures in the medical field. The company has attracted significant interest from investors in the healthcare sector due to its innovative approach and impactful products. Key achievements include the widespread adoption of the ThermaCor 1200 in critical care settings and recognition for improving patient care standards. Overall, Smisson-Cartledge Biomedical has made a substantial impact on the medical device industry by offering life-saving technologies that address critical clinical needs.

Smisson-Cartledge Biomedical - Quick Facts

When was Smisson-Cartledge Biomedical founded?

Smisson-Cartledge Biomedical was founded in 1996.

Where is Smisson-Cartledge Biomedical's headquarters located?

Smisson-Cartledge Biomedical's headquarters is located in Macon, GA, US.

When was Smisson-Cartledge Biomedical's last funding round?

Smisson-Cartledge Biomedical's most recent funding round was for $2M (USD) in July 2012.

How much has Smisson-Cartledge Biomedical raised to-date?

As of Jul 27, 2012, Smisson-Cartledge Biomedical has raised a total of $3.4M (USD).

How many employees does Smisson-Cartledge Biomedical have?

Smisson-Cartledge Biomedical has 20 employees as of Feb 5, 2024.

Smisson-Cartledge Biomedical - Classification

Industry
  • Hardware
Geographic Exposure
  • United States
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Medical Devices
Tags
  • Healthcare
  • Healthtech
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
SIC
  • 5000Wholesale Trade-durable Goods
  • 5040Professional And Commercial Equipment And Supplies
  • 5047Medical, Dental, And Hospital Equipment And Supplies
Show 11 more industry codes
NAICS
  • 423000Merchant Wholesalers, Durable Goods
  • 423400Professional and Commercial Equipment and Supplies Merchant Wholesalers
  • 423450Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers
  • 330000Manufacturing
  • 420000Wholesale Trade
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 3900Miscellaneous Manufacturing Industries
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified